-
公开(公告)号:US20100114309A1
公开(公告)日:2010-05-06
申请号:US12521543
申请日:2007-12-21
IPC分类号: A61F2/16
CPC分类号: A61F9/0017 , A61F9/00772 , A61F9/00781 , A61K9/0051
摘要: An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.
摘要翻译: 用于眼睛的植入物包括可植入结构和治疗剂。 治疗剂可以从结构递送到眼睛中,以便治疗影响和/或稳定眼睛的折射性质。 在许多实施例中,眼睛的屈光性可以包括近视,远视或散光中的至少一种。 治疗剂可以包含治疗影响或稳定眼睛的折射性质的组合物。 治疗剂可以包括散瞳剂或瘫痪药物中的至少一种。 例如,治疗剂可以包括睫状肌麻痹症,其包括阿托品,环戊二酸酯,琥珀酰胆碱,同质素,东莨菪碱或托品酰胺中的至少一种。 在许多实施例中,保持元件可以附接到结构以沿着天然组织表面保持结构。
-
公开(公告)号:US09421126B2
公开(公告)日:2016-08-23
申请号:US13151001
申请日:2011-06-01
申请人: Yair Alster , Eugene de Juan, Jr. , Cary J. Reich , Stephen Boyd , David Sierra , Jose D. Alejandro , K. Angela Macfarlane , Douglas Sutton
发明人: Yair Alster , Eugene de Juan, Jr. , Cary J. Reich , Stephen Boyd , David Sierra , Jose D. Alejandro , K. Angela Macfarlane , Douglas Sutton
IPC分类号: A61F9/00 , A61M35/00 , A61K9/00 , A61K31/19 , A61K31/407 , A61K31/4178 , A61K31/5377 , A61K31/5415 , A61K31/43 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/56 , A61K31/568 , A61K31/573 , A61K31/58 , A61K31/7036 , A61K38/00 , A61M31/00
CPC分类号: A61F9/0026 , A61F9/0017 , A61K9/0051 , A61K31/19 , A61K31/335 , A61K31/407 , A61K31/4178 , A61K31/43 , A61K31/5377 , A61K31/5415 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/56 , A61K31/568 , A61K31/573 , A61K31/58 , A61K31/7036 , A61K38/00 , A61M31/002
摘要: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.
摘要翻译: 治疗系统包括放置在眼睛的光学区域外的区域上的眼部插入物。 眼睛插入件包括两个结构:第一骨架结构和第二缓冲结构。 第一结构用作骨架框架,其保持沿着眼睛前部的植入物的定位,并向第二缓冲结构提供支撑。 该第一结构将治疗系统的附着维持在眼前部至少三十天。 在一些实施例中,第一结构保持恒定的尺寸和形状,例如。 环形,具有触觉的环或曲线环,其限制并限制性地接合下部和上部结膜孔,以将植入物保持在泪液和/或针对眼睛的组织。
-
公开(公告)号:US20110208300A1
公开(公告)日:2011-08-25
申请号:US12897131
申请日:2010-10-04
IPC分类号: A61F2/14
CPC分类号: A61F9/007 , A61F2/142 , A61F2/1451 , A61F2/1453 , A61F9/0017 , A61F2250/0019
摘要: A corneal only is configured to adhere to the cornea so as to inhibit epithelial growth under the onlay. Structures can be provided on the onlay to adhere the onlay to the eye. At least one of an epithelial layer or the water inhibiting layer can be provided on or over the onlay, for example a natural epithelial layer or water inhibiting layer that inhibits, for example minimizes, water penetration into the onlay, so as to adhere the onlay to the eye with pumping of the endothelium. The water inhibiting layer may comprise a therapeutic covering positioned over the onlay to inhibit swelling of the cornea. The posterior surface of the onlay may be shaped so as to fit the anterior exposed surface of the cornea.
摘要翻译: 角膜仅被配置成粘附在角膜上,以便抑制覆盖物下的上皮生长。 可以在镶嵌上提供结构以将贴面粘附到眼睛上。 上皮层或水分抑制层中的至少一个可以设置在覆盖物上或上方,例如天然上皮层或水分抑制层,其抑制例如使水渗入到镶嵌物中的最小程度,以便粘附该覆盖层 通过泵送内皮到眼睛。 防水层可以包括定位在覆层上的治疗覆盖物,以抑制角膜的肿胀。 垫片的后表面可以被成形为适合角膜的前暴露表面。
-
公开(公告)号:US20100036488A1
公开(公告)日:2010-02-11
申请号:US12384659
申请日:2009-04-06
申请人: Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , Yair Alster , David Sierra , Hanson S. Gifford , Jose D. Alejandro , Richard L. Lindstrom , K. Angela Macfariane , Douglas Sutton , John Anthony
发明人: Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , Yair Alster , David Sierra , Hanson S. Gifford , Jose D. Alejandro , Richard L. Lindstrom , K. Angela Macfariane , Douglas Sutton , John Anthony
IPC分类号: A61F2/14
CPC分类号: A61F2/142 , A61F2/14 , A61F9/00 , A61F2250/0067 , G02C7/047
摘要: A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.
摘要翻译: 用于治疗上皮缺损的治疗镜片包括设置在基质和/或Bowman膜上的治疗材料层,以抑制从泪液到基质和/或Bowman膜的水流,使得可以恢复角膜deturgescence 减少角膜肿胀和光散射。 该层可以覆盖并保护神经纤维以减轻疼痛。 该层可以包括折射率以抑制从基质和/或Bowman膜的前表面的光散射。 透镜可以包括弯曲的前表面,当上皮再生时,该前表面为患者提供功能视觉。 治疗材料层可以以许多方式定位在眼睛上,例如通过固化以将该层粘附到基质和/或Bowman膜的暴露表面上的喷雾。
-
公开(公告)号:US10166142B2
公开(公告)日:2019-01-01
申请号:US14236863
申请日:2012-08-03
申请人: Eugene De Juan, Jr. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
发明人: Eugene De Juan, Jr. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
IPC分类号: A61F9/00 , A61K9/00 , A61K31/382 , A61K31/407 , A61K31/519
摘要: A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
-
公开(公告)号:US20140358125A1
公开(公告)日:2014-12-04
申请号:US14236863
申请日:2012-08-03
申请人: Eugene de Juan, JR. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
发明人: Eugene de Juan, JR. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
IPC分类号: A61F9/00 , A61K31/382
CPC分类号: A61F9/0017 , A61F2250/0031 , A61F2250/0068 , A61K9/0051 , A61K31/382 , A61K31/407 , A61K31/519 , F04C2270/041
摘要: A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
摘要翻译: 一种能够释放治疗剂的治疗装置,所述治疗剂包括与包含储存器的容器相连的多孔结构。 贮存器可以包含一定量的体积,当耦合到多孔结构并且植入患者体内时,释放处理量的治疗剂延长时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第二侧的距离的有效长度。 治疗装置可以包括当植入患者时将治疗剂注射到装置中的可穿透屏障。
-
公开(公告)号:US20140031769A1
公开(公告)日:2014-01-30
申请号:US13988298
申请日:2011-11-18
申请人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson , Blaine Bueche
发明人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson , Blaine Bueche
IPC分类号: A61F9/00
CPC分类号: A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K9/1652 , A61K31/573
摘要: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.
摘要翻译: 治疗剂的可注射制剂可以包含治疗剂和稳定剂,使得当治疗剂从治疗装置释放时,大部分稳定剂保留在治疗装置中以稳定治疗剂。 可注射制剂可以包含一种或多种粘合剂颗粒或可侵蚀材料颗粒,使得可以将制剂注射到治疗装置中。 结合剂颗粒可以可逆地结合治疗剂以调节治疗剂的释放,并且可侵蚀的材料颗粒可以产生酸的质子,以增加治疗剂的稳定性并且可以调节治疗剂的释放。 治疗剂可以与稳定剂,结合剂颗粒或可侵蚀颗粒中的一种或多种组合以增加治疗剂的稳定性并且可以调节释放。
-
公开(公告)号:US20140028979A1
公开(公告)日:2014-01-30
申请号:US13885135
申请日:2011-10-25
申请人: Eugene De Juan ,Jr. , Yair Alster , Cary J. Reich , Ashley Tuan , Angela K. MacFarlane , Matt Clarke , Brian Levy
发明人: Eugene De Juan ,Jr. , Yair Alster , Cary J. Reich , Ashley Tuan , Angela K. MacFarlane , Matt Clarke , Brian Levy
CPC分类号: G02C7/047 , A61B3/0025 , A61B3/0041 , A61B3/1005 , A61B3/1015 , A61B3/107 , A61B3/18 , A61F9/00804 , A61F9/00806 , A61F9/04 , A61F2009/00859 , A61F2009/00872 , G02C7/027 , G02C7/04 , G02C7/048 , G02C7/049 , G02C2202/16
摘要: Methods and apparatus can fit coverings to treat eyes. The covering can be identified so as to provide improved flow of tear liquid under the covering. The covering can be identified based on an inner corneal curvature and an outer corneal curvature and one or more of a limbus sag height or a conjunctival sag height. The covering may form a chamber when placed on the eye to pump tear liquid under at least a portion of the covering. The covering may comprise an outer portion with rigidity to resist movement on the cornea and an inner portion to contact the cornea and provide an environment for epithelial regeneration. The covering may comprise a material having high oxygen permeability, for example silicone, with a wettable coating disposed on at least an upper surface of the coating.
摘要翻译: 方法和装置可以配合护理眼睛。 可以识别覆盖物,以便在覆盖物下方提供改善的泪液流动。 可以基于内部角膜曲率和外部角膜曲率以及角膜缘下垂高度或结膜下垂高度中的一个或多个来识别覆盖物。 当覆盖物放置在眼睛上时,该覆盖物可以形成一个室,以在至少一部分覆盖物之下泵送泪液。 覆盖物可以包括具有刚性以抵抗角膜上的运动的外部部分和与角膜接触的内部部分,并提供用于上皮再生的环境。 覆盖物可以包括具有高氧渗透性的材料,例如硅树脂,其中可湿性涂层设置在涂层的至少上表面上。
-
公开(公告)号:US20130324942A1
公开(公告)日:2013-12-05
申请号:US13814464
申请日:2011-08-05
申请人: Eugene de Juan, JR. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell
发明人: Eugene de Juan, JR. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell
IPC分类号: A61F9/00
CPC分类号: A61F9/0017 , A61K9/0051
摘要: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the 188 second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
摘要翻译: 用于释放治疗剂的治疗装置包括联接到包括储存器的容器的多孔结构。 储存器包括体积大小,当耦合到多孔结构并且植入患者体内时,释放治疗剂量的治疗剂延长的时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第188侧的距离的有效长度。 治疗装置可以包括当植入患者时将治疗剂注射到装置中的可穿透屏障。
-
公开(公告)号:US20130070200A1
公开(公告)日:2013-03-21
申请号:US13503842
申请日:2010-10-25
申请人: Eugene de Juan, JR. , Cary J. Reich , Yair Alster , K. Angela Macfarlane , Doug Rimer , Douglas Sutton , Dean Carson , Enrique Barragan , Matt Clarke , Ashley Tuan , Brian Levy
发明人: Eugene de Juan, JR. , Cary J. Reich , Yair Alster , K. Angela Macfarlane , Doug Rimer , Douglas Sutton , Dean Carson , Enrique Barragan , Matt Clarke , Ashley Tuan , Brian Levy
CPC分类号: G02C7/047 , A61F2/145 , A61F2/147 , A61F9/00 , A61F9/0017 , A61F9/008 , A61F9/00802 , A61F9/00804 , A61F9/013 , A61F9/0136 , A61F9/04 , A61F13/124 , A61F2009/00853 , A61F2009/00893 , A61F2250/0029 , A61L27/18 , A61L2430/16 , G02C7/048 , G02C7/049 , G02C2202/06 , C08L83/04
摘要: A conformable covering comprises an outer portion with rigidity to resist movement on the cornea and an inner portion to contact the cornea and provide an environment for epithelial regeneration. The inner portion of the covering can be configured in many ways so as to conform at least partially to an ablated stromal surface so as to correct vision. The conformable inner portion may have at least some rigidity so as to smooth the epithelium such that the epithelium regenerates rapidly and is guided with the covering so as to form a smooth layer for vision. The inner portion may comprise an amount of rigidity within a range from about 1×10−4 Pa*m3 to about 5×10−4 Pa*m3 so as to deflect and conform at least partially to the ablated cornea and smooth an inner portion of the ablation with an amount of pressure when deflected.
-
-
-
-
-
-
-
-
-